143 related articles for article (PubMed ID: 34182131)
21. Prostacyclin protects against elevated blood pressure and cardiac fibrosis.
Francois H; Athirakul K; Howell D; Dash R; Mao L; Kim HS; Rockman HA; Fitzgerald GA; Koller BH; Coffman TM
Cell Metab; 2005 Sep; 2(3):201-7. PubMed ID: 16154102
[TBL] [Abstract][Full Text] [Related]
22. Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy.
Manninen A
Pharmacol Toxicol; 1996 Jun; 78(6):387-91. PubMed ID: 8829198
[TBL] [Abstract][Full Text] [Related]
23. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809
[TBL] [Abstract][Full Text] [Related]
24. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
Clarke RJ; Mayo G; Price P; FitzGerald GA
N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
[TBL] [Abstract][Full Text] [Related]
25. Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects.
Weber AA; Liesener S; Schanz A; Hohlfeld T; Schrör K
Platelets; 2000 May; 11(3):177-82. PubMed ID: 10938895
[TBL] [Abstract][Full Text] [Related]
26. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
[TBL] [Abstract][Full Text] [Related]
27. Platelet hypersensitivity in cholesterol-fed rabbits: enhancement of thromboxane A2-dependent and thrombin-induced, thromboxane A2-independent platelet responses.
Gross PL; Rand ML; Barrow DV; Packham MA
Atherosclerosis; 1991 May; 88(1):77-86. PubMed ID: 1878012
[TBL] [Abstract][Full Text] [Related]
28. Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen.
Wagner WR; Hubbell JA
J Lab Clin Med; 1992 Jun; 119(6):690-7. PubMed ID: 1534345
[TBL] [Abstract][Full Text] [Related]
29. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn.
Viinikka L; Hartikainen-Sorri AL; Lumme R; Hiilesmaa V; Ylikorkala O
Br J Obstet Gynaecol; 1993 Sep; 100(9):809-15. PubMed ID: 8217999
[TBL] [Abstract][Full Text] [Related]
30. Thromboxane A2 induces blood flow recovery via platelet adhesion to ischaemic regions.
Amano H; Ito Y; Eshima K; Kato S; Ogawa F; Hosono K; Oba K; Tamaki H; Sakagami H; Shibuya M; Narumiya S; Majima M
Cardiovasc Res; 2015 Sep; 107(4):509-21. PubMed ID: 25935870
[TBL] [Abstract][Full Text] [Related]
31. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
Keimowitz RM; Pulvermacher G; Mayo G; Fitzgerald DJ
Circulation; 1993 Aug; 88(2):556-61. PubMed ID: 8339418
[TBL] [Abstract][Full Text] [Related]
32. Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia.
Yamada M; Omata K; Abe F; Ito S; Abe K
Immunopharmacology; 1999 Oct; 44(1-2):193-8. PubMed ID: 10604544
[TBL] [Abstract][Full Text] [Related]
33. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia.
Cavalca V; Rocca B; Squellerio I; Dragani A; Veglia F; Pagliaccia F; Porro B; Barbieri SS; Tremoli E; Patrono C
Thromb Haemost; 2014 Jul; 112(1):118-27. PubMed ID: 24671522
[TBL] [Abstract][Full Text] [Related]
34. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
35. Significance of urinary 11-dehydro-thromboxane B
Simeone P; Boccatonda A; Liani R; Santilli F
Ageing Res Rev; 2018 Dec; 48():51-78. PubMed ID: 30273676
[TBL] [Abstract][Full Text] [Related]
36. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.
Landolfi R; Ciabattoni G; Patrignani P; Castellana MA; Pogliani E; Bizzi B; Patrono C
Blood; 1992 Oct; 80(8):1965-71. PubMed ID: 1327286
[TBL] [Abstract][Full Text] [Related]
37. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production.
Riondino S; Trifirò E; Principessa L; Mascioletti S; Di Renzo L; Gaudio C; Biasucci LM; Crea F; Pulcinelli FM
Thromb Res; 2008; 122(3):359-65. PubMed ID: 18295304
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
Terashita Z; Imura Y; Nishikawa K
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
[TBL] [Abstract][Full Text] [Related]
39. Failure of aspirin to impair bovine platelet function.
Gentry PA; Tremblay RR; Ross ML
Am J Vet Res; 1989 Jun; 50(6):919-22. PubMed ID: 2764343
[TBL] [Abstract][Full Text] [Related]
40. The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces intestinal polyposis in Apc
Bruno A; Contursi A; Tacconelli S; Sacco A; Hofling U; Mucci M; Lamolinara A; Del Pizzo F; Ballerini P; Di Gregorio P; Yu Y; Patrignani P
Pharmacol Res; 2022 Nov; 185():106506. PubMed ID: 36241001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
